An observational study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM), sponsored by Bayer. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Bayer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart. This buildup can make it harder for the heart to pump blood and may lead to worsening symptoms over time. Acoramidis is a medicine approved for the treatment of adults with wild-type or hereditary (variant) ATTR-CM. While its benefits have been demonstrated in clinical trials, more information is needed about how it is used and how patients do in everyday medical practice.
The MOSAIC-TTR study is an observational study in France. Participants will receive acoramidis as part of their usual medical care. No experimental treatments or additional medical procedures will be required. The study will collect information directly from participating hospitals and from the Healthcare European Amyloidosis Registry (HEAR; NCT05101304). The main goal of the study is to understand how patients' quality of life, daily functioning, and overall well-being change during the first 12 months of treatment with acoramidis, using questionnaires completed by the patients themselves. The study will also collect information about the characteristics of patients receiving acoramidis, how the medicine is used in routine clinical practice, and its safety and tolerability. The information collected will help improve the understanding of ATTR-CM and may help improve the care of people living with this condition.
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants will be recruited from centers that are part of the French Amyloidosis Network or centers that are knowledgeable in the diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM). There are two complementary enrollment pathways: (i) direct recruitment within this study, and (ii) integration of data from the Healthcare Amyloidosis European Registry (HEAR), a multicenter registry maintained by reference centers (see NCT05101304), to enrich the study database.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive acoramidis 712 mg orally BID (twice daily)
Drug: Acoramidis
356 mg film-coated tablets. The recommended dose is 712 mg (two tables, 356 mg) orally twice daily, corresponding to a total daily dose of 1424 mg.
Also known as: BAY3684938, BEYONTTRA
Patient Reported Outcome Measure: Amylo-AFFECT-QOL score
Change from baseline in Amylo-AFFECT-QOL total score
Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis
Patient Reported Outcome Measure: KCCQ-23 score
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ-23) total score
Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis
Patient Reported Outcome Measure: EQ-5D-3L index score
3L index score of EQ-5D Health-Related Quality of Life Questionnaire
Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis
Patient Reported Outcome Measure: EQ VAS score
Visual Analog scale score of EQ-5D Health-Related Quality of Life Questionnaire
Time frame: At 3, 6, 9, and 12 months after initiation of acoramidis
Demographic characteristics: Age
Age of patients initiating treatment with acoramidis
Time frame: Before treatment with acoramidis
Demographic characteristics: Sex
Sex of patients initiating treatment with acoramidis
Time frame: Before treatment with acoramidis
Demographic characteristics: Body Mass Index
Body Mass Index of patients initiating treatment with acoramidis
Time frame: Before treatment with acoramidis
Clinical characteristics: Time between diagnosis and treatment initiation
Time between ATTR-CM diagnosis and treatment initiation
Time frame: Before treatment with acoramidis
Clinical characteristics: ATTR-CM diagnosis
ATTR-CM diagnosis (genetic status including mutation type \[if applicable\], phenotype)
Time frame: Before treatment with acoramidis
Clinical characteristics: ATTR-CM manifestations
ATTR-CM manifestations prior to treatment initiation
Time frame: Before treatment with acoramidis
Clinical characteristics: Comorbidities
ATTR-CM-relevant comorbidities that were either ongoing at treatment initiation, or were previously managed or resolved in the 12 months prior to initiating acoramidis, as well as those that began after initiating acoramidis
Time frame: Up to 12 months before initiation of acoramidis, and during treatment with acoramidis
Clinical characteristics: Prior medication and procedures
Prior medication taken and procedures performed up to 12 months before initiation of acoramidis
Time frame: Up to 12 months before initiation of acoramidis
Treatment patterns: Treatment duration
Duration of treatment with acoramidis
Time frame: During treatment with acoramidis
Treatment patterns: Treatment interruptions
Proportion of patients with temporary treatment interruptions and reason for interruption
Time frame: During treatment with acoramidis
Treatment patterns: Treatment discontinuation
Proportion of patients with permanent treatment discontinuation and reason for discontinuation
Time frame: During treatment with acoramidis
Treatment patterns: Time to treatment discontinuation
Time to acoramidis treatment discontinuation
Time frame: During treatment with acoramidis
Treatment patterns: Concomitant medications and procedures
Concomitant medications taken and procedures performed during treatment with acoramidis
Time frame: During treatment with acoramidis
Safety and tolerability: Adverse events
Adverse events (AEs) occurring during treatment with acoramidis and AEs occurring up to 6 days after the last intake of acoramidis if premature permanent treatment discontinuation
Time frame: During treatment with acoramidis and up to 6 days after the last intake of acoramidis in case of premature permanent treatment discontinuation
Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2028, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.